4.4 Article

Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy

Journal

NEUROSCIENCE LETTERS
Volume 433, Issue 1, Pages 65-70

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2007.12.064

Keywords

sodium channels; SCN3A; epilepsy

Categories

Funding

  1. NHLBI NIH HHS [R01 HL056810-10A1, HL56810, R01 HL056810] Funding Source: Medline
  2. NINDS NIH HHS [NS34509, R01 NS053792, R01 NS034509, R01 NS053792-03, R01 NS034509-11A2, NS053792] Funding Source: Medline

Ask authors/readers for more resources

Mutations in the sodium channel genes SCN1A and SCN2A have been identified in monogenic childhood epilepsies, but SCN3A has not previously been investigated as a candidate gene for epilepsy. We screened a consecutive cohort of 18 children with cryptogenic partial epilepsy that was classified as pharmacoresistant because of nonresponse to carbamazepine or oxcarbazepine, antiepileptic drugs that bind sodium channels. The novel coding variant SCN3A-K354Q was identified in one patient and was not present in 295 neurological normal controls. Twelve novel SNPs were also detected. K354Q substitutes glutamine for an evolutionarily conserved lysine residue in the pore domain of SCN3A. Functional analysis of this mutation in the backbone of the closely related gene SCN5A demonstrated an increase in persistent current that is similar in magnitude to epileptogenic mutations of SCN1A and SCN2A. This observation of a potentially pathogenic mutation of SCN3A (Nav 1.3) indicates that this gene should be further evaluated for its contribution to childhood epilepsy. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available